Table 3.
The results of association analysis between relative expressions of genes in tumoral tissues compared with ANCTs and patients’ clinicopathological data (up/downregulation of genes was defined based on relative expression of each gene in tumoral tissue compared with the corresponding ANCT. Patients with higher expression of genes in tumoral tissue compared with the paired ANCT were classified as upregulation (fold change > 1) and vice versa)
| SOCS1 upregulation | SOCS1 downregulation | P value | SOCS2 upregulation | SOCS2 downregulation | P value | SOCS3 upregulation | SOCS3 downregulation | P value | SOCS5 upregulation | SOCS5 downregulation | P value | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0.35 | 0.5 | 0.84 | 0.68 | ||||||||
| < 55 years | 11 (32.4%) | 23 (67.6%) | 9 (26.5%) | 25 (73.5%) | 11 (32.4%) | 23 (67.6%) | 10 (29.4%) | 24 (70.6%) | ||||
| ≥ 55 years | 9 (45%) | 11 (55%) | 7 (35%) | 13 (65%) | 7 (35%) | 13 (65%) | 5 (25%) | 15 (75%) | ||||
| Stage | 0.95 | 0.81 | 0.8 | 0.86 | ||||||||
| 1 | 5 (31.3%) | 11 (68.7%) | 5 (31.3%) | 11 (68.7%) | 4 (25%) | 12 (75%) | 3 (18.8%) | 13 (81.2%) | ||||
| 2 | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 5 (33.3%) | 10 (66.7%) | ||||
| 3 | 7 (43.8%) | 9 (56.3%) | 4 (25%) | 12 (75%) | 5 (31.2%) | 11 (68.8%) | 5 (31.2%) | 11 (68.8%) | ||||
| 4 | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | ||||
| Histological grade | 0.32 | 0.18 | 0.08 | 0.19 | ||||||||
| 1 | 2 (25%) | 6 (75%) | 1 (12.5%) | 7 (87.5%) | 0 (0%) | 8 (100%) | 0 (0%) | 8 (100%) | ||||
| 2 | 12 (52.2%) | 11 (47.8%) | 10 (43.5%) | 13 (56.5%) | 9 (39.1%) | 14 (60.9%) | 8 (34.8%) | 15 (65.2%) | ||||
| 3 | 5 (31.3%) | 11 (68.8%) | 3 (18.8%) | 13 (81.2%) | 7 (43.8%) | 9 (56.2%) | 4 (25%) | 12 (75%) | ||||
| Mitotic rate | 0.36 | 0.03 | 0.9 | 0.16 | ||||||||
| 1 | 10 (52.6%) | 9 (47.4%) | 10 (52.6%) | 9 (47.4%) | 8 (42.1%) | 11 (57.9%) | 8 (42.1%) | 11 (57.9%) | ||||
| 2 | 6 (33.3%) | 12 (66.7%) | 4 (22.2%) | 14 (77.8%) | 6 (33.3%) | 12 (66.7%) | 4 (22.2%) | 14 (77.8%) | ||||
| 3 | 1 (20%) | 4 (80%) | 0 (0%) | 5 (100%) | 2 (40%) | 3 (60%) | 0 (0%) | 5 (100%) | ||||
| Tumor size | 0.26 | 0.29 | 1 | 0.38 | ||||||||
| < 2 | 4 (25%) | 12 (75%) | 5 (31.3%) | 11 (68.8%) | 5 (31.3%) | 11 (68.8%) | 4 (25%) | 12 (75%) | ||||
| 2–5 | 15 (45.5%) | 18 (54.5%) | 9 (27.3%) | 24 (72.7%) | 11 (33.3%) | 12 (66.7%) | 8 (24.2%) | 25 (75.8%) | ||||
| > 5 | 0 (0%) | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 1 (100%) | 0 (0%) | ||||
| ER state | 0.81 | 0.63 | 1 | 0.36 | ||||||||
| Positive | 16 (38.1%) | 26 (61.9%) | 13 (31%) | 29 (69%) | 14 (33.3%) | 28 (66.7%) | 10 (23.8%) | 32 (76.2%) | ||||
| Negative | 3 (42.9%) | 4 (57.1%) | 2 (28.6%) | 5 (71.4%) | 2 (28.6%) | 5 (71.4%) | 3 (42.9%) | 4 (57.1%) | ||||
| PR state | 0.8 | 0.72 | 0.33 | 0.45 | ||||||||
| Positive | 15 (40.5%) | 22 (59.5%) | 11 (29.7%) | 26 (70.3%) | 11 (29.7%) | 26 (70.3%) | 9 (24.3%) | 28 (75%) | ||||
| Negative | 4 (36.4%) | 7 (63.6%) | 4 (36.4%) | 7 (63.6%) | 5 (45.5%) | 6 (54.5%) | 4 (36.4%) | 7 (63.6%) | ||||
| Her2 state | 0.39 | 0.85 | 0.15 | 0.18 | ||||||||
| Positive | 6 (50%) | 6 (50%) | 4 (33.3%) | 8 (66.7%) | 6 (50%) | 6 (50%) | 5 (41.7%) | 7 (58.3%) | ||||
| Negative | 13 (36.1%) | 23 (63.9%) | 11 (30.6%) | 25 (69.4%) | 10 (27.8%) | 26 (72.2%) | 8 (22.2%) | 28 (77.8%) | ||||
| Breast feeding duration (months) | 0.3 | 0.84 | 0.08 | 0.19 | ||||||||
| 0 | 4 (50%) | 4 (50%) | 2 (25%) | 6 (75%) | 5 (62.5%) | 3 (37.5%) | 4 (50%) | 4 (50%) | ||||
| 1–30 | 8 (53.3%) | 7 (46.7%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | ||||
| 31–60 | 5 (27.8%) | 13 (72.2%) | 5 (27.8%) | 13 (72.2%) | 6 (33.3%) | 12 (66.7%) | 3 (16.7%) | 15 (83.3%) | ||||
| 61–120 | 3 (25%) | 9 (75%) | 3 (25%) | 9 (75%) | 1 (8.3%) | 11 (91.7%) | 2 (16.7%) | 10 (83.3%) | ||||